ArticleNature microbiology2018
Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis.
Article in Nature microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
172 citing papers in PubMed, 294 citations in OpenAlex.
- Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.Science translational medicine · 2021Trial
- Genomic features of mecA-harboring Staphylococcus epidermidis infecting an illegally traded rufous-bellied thrush (T. rufiventris).Veterinary research communications · 2026Article
- Clonal dissemination of linezolid-resistantInfection prevention in practice · 2026Article
- Insertion sequence elements associated with Staphylococcus epidermidis evolution in persistent orthopaedic device-related infections.BMC genomics · 2026Article
- Phenotypic characterization, molecular typing, and clonal relatedness within Staphylococcus isolates in healthy ocular conditions.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Global distribution, antimicrobial resistance, and virulence factors of Staphylococcus epidermidis revealed through population genomics.BMC genomics · 2026Article
- Comparative genomics of methicillin-resistant and -susceptibleMicrobiology spectrum · 2026Article
- Of Commensals and Opportunists: Genomics of Coagulase-Negative Staphylococci During Sequential Ear and Eye Infections in a Healthy Adult.MicrobiologyOpen · 2026Article
- The Evolution of Symbiosis inBiomolecules · 2026Review
- Article
- Beyond the skin barrier: commensalbioRxiv : the preprint server for biology · 2026Article
- The Scalp Microbiome-Hair Axis: Mechanisms and Therapeutic Translation.Research (Washington, D.C.) · 2026Review
- Genomic characterization of Staphylococcus epidermidis Se252 isolated from the rhizosphere of a Brazilian endemic plant.BMC genomics · 2025Article
- Wounds and the Microbiota: The Healing Interplay Between Host and Microbial Communities.International journal of molecular sciences · 2025Review
- Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.The Journal of antimicrobial chemotherapy · 2025Article
- Pre-trained ChatGPT for report generation in automated microbial identification and antibiotic susceptibility testing systems.Scientific reports · 2025Article
- A new approach for establishing multilocus sequence typing scheme: Staphylococcus capitis as an example.BMC microbiology · 2025Article
- Prophylactic efficacy of probiotics and their metabolites against Staphylococcus epidermidis.BMC microbiology · 2025Article
- From colonizer to culprit: genomic and clinical insights into S. epidermidis from post-surgical endophthalmitis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Review
112 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 11 institutions in 7 countries.
Funding
Abstract
Staphylococcus epidermidis is a conspicuous member of the human microbiome, widely present on healthy skin. Here we show that S. epidermidis has also evolved to become a formidable nosocomial pathogen. Using genomics, we reveal that three multidrug-resistant, hospital-adapted lineages of S. epidermidis (two ST2 and one ST23) have emerged in recent decades and spread globally. These lineages are resistant to rifampicin through acquisition of specific rpoB mutations that have become fixed in the populations. Analysis of isolates from 96 institutions in 24 countries identified dual D471E and I527M RpoB substitutions to be the most common cause of rifampicin resistance in S. epidermidis, accounting for 86.6% of mutations. Furthermore, we reveal that the D471E and I527M combination occurs almost exclusively in isolates from the ST2 and ST23 lineages. By breaching lineage-specific DNA methylation restriction modification barriers and then performing site-specific mutagenesis, we show that these rpoB mutations not only confer rifampicin resistance, but also reduce susceptibility to the last-line glycopeptide antibiotics, vancomycin and teicoplanin. Our study has uncovered the previously unrecognized international spread of a near pan-drug-resistant opportunistic pathogen, identifiable by a rifampicin-resistant phenotype. It is possible that hospital practices, such as antibiotic monotherapy utilizing rifampicin-impregnated medical devices, have driven the evolution of this organism, once trivialized as a contaminant, towards potentially incurable infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.